CNTN2 and neoplasm: This led to discard the TaG3 FGFR3-mutated tumors (4% of FGFR3-mutated cases in the first data set) and the TaG1, G2 FGFR3-non-mutated tumors (9% of FGFR3-non-mutated cases in the first data set), as in these two subgroups the FGFR3 mutation was likely not the correct parameter for classifying a tumor in one of the two pathways (see paragraph on “Model of bladder cancer pathogenesis used in this study” in the Results section).